Skip to content

Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood

Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02261831
Acronym
MICIMAB
Enrollment
99
Registered
2014-10-10
Start date
2014-02-28
Completion date
2017-12-31
Last updated
2018-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

bacterial, gut, type 2 diabetes., 16S rDNA gene, intestinal crypt

Brief summary

The investigators will compare 16sRDNA profile in cases and controls in order to identify bacteria associated with metabolic diseases that reside both in intestinal crypts and in blood.

Detailed description

Experimental evidence suggests that bacterial translocation from gut to tissue could be an initial step leading to diabetes. To test this hypothesis, a bacterial component that is highly conserved between different species of bacteria, the 16S rDNA gene will be analysed both in intestinal crypt and in blood in patients with type 2 diabetes, obese patients and control.

Interventions

OTHERpatients free type 2 diabetes

collection of blood sampling and biopsies

OTHERobese patients

collection of blood sampling and biopsies

OTHERdiabetic patients

collection of blood sampling and biopsies

OTHERpatients free of obesity and diabetes

collection of blood sampling and biopsies

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Between 35 and 75 years old * Colonoscopy and biopsies required Diabetes population: * Type 2 diabetes Obese population: * Android obesity

Exclusion criteria

* Inflammatory bowel disease * Colonic cancer * Bariatric surgery * Previous administration of antibiotic (within 15 days) * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
rDNA comparison between cases and controls36 monthsComparison of 16sRDNA profile in cases and controls in order to identify bacteria associated with metabolic diseases that reside both in intestinal crypts and in blood.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026